Technical Analysis for ARNA - Arena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 43.23 -5.32% -2.43
ARNA closed down 5.32 percent on Friday, March 22, 2019, on 1.22 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ARNA trend table...

Date Alert Name Type % Chg
Mar 22 180 Bearish Setup Bearish Swing Setup 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Pocket Pivot Bullish Swing Setup -5.32%
Mar 21 Inside Day Range Contraction -5.32%
Mar 21 Oversold Stochastic Weakness -5.32%
Mar 20 Expansion Pivot Sell Setup Bearish Swing Setup -2.94%
Mar 20 Stochastic Reached Oversold Weakness -2.94%
Mar 20 Down 3 Days in a Row Weakness -2.94%
Mar 20 Oversold Stochastic Weakness -2.94%
Mar 19 50 DMA Resistance Bearish -5.86%

Older signals for ARNA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company offers BELVIQ, a drug candidate approved by the United States food and drug administration for chronic weight management in adults. It is also involved in the development of APD811, an agonist of the prostacyclin receptor, which is in Phase I clinical trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor that is in Phase I clinical trials for the treatment of thrombotic diseases. In addition, the company's preclinical development products comprise APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists intended for the treatment of type 2 diabetes. Further, it manufactures drug products under a manufacturing services agreement. The company has a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd. for the commercialization of BELVIQ in South Korea. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Chemistry Health Biopharmaceutical Food Pain Diabetes Medication Autoimmune Diseases Pharmacology Pulmonary Arterial Hypertension Metabolic Diseases Treatment Of Autoimmune Diseases Inflammatory Cannabinoids Chronic Weight Management Manufacturing Services Agreement United States Food And Drug Administration
Is ARNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 51.63
52 Week Low 31.97
Average Volume 444,798
200-Day Moving Average 42.2123
50-Day Moving Average 46.4756
20-Day Moving Average 47.045
10-Day Moving Average 45.493
Average True Range 1.6412
ADX 22.13
+DI 13.8576
-DI 25.7145
Chandelier Exit (Long, 3 ATRs ) 46.7064
Chandelier Exit (Short, 3 ATRs ) 48.0136
Upper Bollinger Band 51.3797
Lower Bollinger Band 42.7103
Percent B (%b) 0.06
BandWidth 18.427888
MACD Line -0.6871
MACD Signal Line -0.2505
MACD Histogram -0.4366
Fundamentals Value
Market Cap 1.69 Billion
Num Shares 39.2 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -58.42
Price-to-Sales 8.96
Price-to-Book 12.74
PEG Ratio 0.45
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 46.91
Resistance 3 (R3) 47.28 46.41 46.30
Resistance 2 (R2) 46.41 45.47 46.23 46.09
Resistance 1 (R1) 44.82 44.89 44.39 44.46 45.89
Pivot Point 43.96 43.96 43.74 43.77 43.96
Support 1 (S1) 42.37 43.02 41.93 42.00 40.57
Support 2 (S2) 41.50 42.44 41.32 40.37
Support 3 (S3) 39.91 41.50 40.16
Support 4 (S4) 39.55